EFFICACY AND SAFETY OF LOW-DOSE TOPICAL ATROPINE FOR THE PREVENTION OF MYOPIA PROGRESSION IN CHILDREN: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.31435/ijitss.4(52).2026.6775Keywords:
Low-Dose Atropine, Childhood Myopia, Myopia Progression, Axial Length, Safety, Rebound EffectAbstract
Background: Myopia poses a significant global health challenge. Preventing childhood axial elongation is essential for reducing the lifetime risk of severe ocular complications. Low-dose topical atropine (≤ 0.05%) is a promising intervention, but its optimal concentration and long-term safety profile remain debated.
Aim: To systematically evaluate the efficacy (changes in spherical equivalent refraction [SER] and axial length [AL]) and safety of low-dose topical atropine in slowing childhood myopia.
Materials and methods: A systematic search of the PubMed database was conducted on July 8, 2026, following the PRISMA guidelines. Out of 103 identified records, 46 studies (including 36 randomized controlled trials) evaluating pediatric patients (<18 years) treated with atropine (≤ 0.05%) versus placebo or standard care were included.
Results: Results: Most studies demonstrated a significant deceleration in SER progression and AL elongation with low-dose atropine compared to placebo. Efficacy was dose-dependent, with 0.05% atropine showing superior clinical results over 0.025% and 0.01%, but also a more pronounced rebound effect after discontinuation. Active therapy effectively mitigated rapid progression (≥ 0.50 to 0.75 D/year). Adverse events were mild and transient; photophobia and accommodation paralysis were most common, while allergic conjunctivitis was primarily associated with the preservative benzalkonium chloride (BAK). Systemic complications were exceptionally rare.
Conclusion: Low-dose atropine is a highly effective and safe treatment option. Although a 0.05% concentration offers the highest efficacy, it carries a greater risk of rebound. Lower doses (such as 0.01%) provide an excellent safety profile and minimal rebound effect, ensuring high long-term compliance.
References
Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-42. https://doi.org/10.1016/j.ophtha.2016.01.006 Epub 2016 Feb 11. PMID: 26875007.
Wolffsohn JS, Flitcroft DI, Gifford KL, Jong M, Jones L, Klaver CCW, Logan NS, Naidoo K, Resnikoff S, Sankaridurg P, Smith EL 3rd, Troilo D, Wildsoet CF. IMI - Myopia Control Reports Overview and Introduction. Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M1-M19. https://doi.org/10.1167/iovs.18-25980 PMID: 30817825; PMCID: PMC6735780.
Flitcroft DI, He M, Jonas JB, Jong M, Naidoo K, Ohno-Matsui K, Rahi J, Resnikoff S, Vitale S, Yannuzzi L. IMI - Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies. Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M20-M30. https://doi.org/10.1167/iovs.18-25957. Erratum in: Invest Ophthalmol Vis Sci. 2024 Nov 4;65(13):19.https://doi.org/10.1167/iovs.65.13.19. PMID: 30817826; PMCID: PMC6735818
Xiong S, Sankaridurg P, Naduvilath T, Zang J, Zou H, Zhu J, Lv M, He X, Xu X. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017 Sep;95(6):551-566. https://doi.org/10.1111/aos.13403 Epub 2017 Mar 2. PMID: 28251836; PMCID: PMC5599950.
Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. Ophthalmology. 2016 Feb;123(2):391-399. https://doi.org/10.1016/j.ophtha.2015.07.004 Epub 2015 Aug 11. PMID: 26271839.
Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. 2019 Jan;126(1):113-124. https://doi.org/10.1016/j.ophtha.2018.05.029 Epub 2018 Jul 6. PMID: 30514630.
Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, Kam KW, Ko ST, Yip BHK, Young AL, Tham CC, Chen LJ, Pang CP. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Ophthalmology. 2022 Mar;129(3):308-321. https://doi.org/10.1016/j.ophtha.2021.10.002 Epub 2021 Oct 7. PMID: 34627809. [7]
Li Y, Yip M, Ning Y, Chung J, Toh A, Leow C, Liu N, Ting D, Schmetterer L, Saw SM, Jonas JB, Chia A, Ang M. Topical Atropine for Childhood Myopia Control: The Atropine Treatment Long-Term Assessment Study. JAMA Ophthalmol. 2024 Jan 1;142(1):15-23. https://doi.org/10.1001/jamaophthalmol.2023.5467 PMID: 38019503; PMCID: PMC10690578.
Nucci P, Lembo A, Schiavetti I, Shah R, Edgar DF, Evans BJW. A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine. PLoS One. 2023 Feb 16;18(2):e0281816. https://doi.org/10.1371/journal.pone.0281816 PMID: 36795775; PMCID: PMC9934319.
Zhang XJ, Zhang Y, Yip BHK, Kam KW, Tang F, Ling X, Ng MPH, Young AL, Wu PC, Tham CC, Chen LJ, Pang CP, Yam JC. Five-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report. Ophthalmology. 2024 Sep;131(9):1011-1020. https://doi.org/10.1016/j.ophtha.2024.03.013 Epub 2024 Mar 16. PMID: 38494130.
Sharma I, Das GK, Rohatgi J, Sahu PK, Chhabra P, Bhatia R. Low Dose Atropine in Preventing the Progression of Childhood Myopia: A Randomised Controlled Trial. Curr Eye Res. 2023 Apr;48(4):402-407. https://doi.org/10.1080/02713683.2022.2162925 Epub 2022 Dec 29. PMID: 36576170.
Wang Z, Li T, Zuo X, Zhang T, Liu L, Zhou C, Leng Z, Chen X, Wang L, Wang X, Liu H. 0.01% Atropine Eye Drops in Children With Myopia and Intermittent Exotropia: The AMIXT Randomized Clinical Trial. JAMA Ophthalmol. 2024 Aug 1;142(8):722-730. https://doi.org/10.1001/jamaophthalmol.2024.2295 PMID: 38958962; PMCID: PMC11223046.
Loughman J, Lingham G, Nkansah EK, Kobia-Acquah E, Flitcroft DI. Efficacy and Safety of Different Atropine Regimens for the Treatment of Myopia in Children: Three-Year Results of the MOSAIC Randomized Clinical Trial. JAMA Ophthalmol. 2025 Feb 1;143(2):134-144. https://doi.org/10.1001/jamaophthalmol.2024.5703 PMID: 39786755; PMCID: PMC11843376.
Li FF, Zhang Y, Zhang X, Yip BHK, Tang SM, Kam KW, Young AL, Chen LJ, Tham CC, Pang CP, Yam JC. Age Effect on Treatment Responses to 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study. Ophthalmology. 2021 Aug;128(8):1180-1187. https://doi.org/10.1016/j.ophtha.2020.12.036 Epub 2021 Jan 8. PMID: 33422558.
Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. Ophthalmology. 2020 Jul;127(7):910-919. https://doi.org/10.1016/j.ophtha.2019.12.011 Epub 2019 Dec 21. PMID: 32019700.
Sen S, Yadav H, Jain A, Verma S, Gupta P. Effect of atropine 0.01% on progression of myopia. Indian J Ophthalmol. 2022 Sep;70(9):3373-3376. https://doi.org/10.4103/ijo.IJO_256_22. PMID: 36018124; PMCID: PMC9675497.
Sharma I, Das GK, Rohatgi J, Sahu PK, Chhabra P, Bhatia R. Low Dose Atropine in Preventing the Progression of Childhood Myopia: A Randomised Controlled Trial. Curr Eye Res. 2023 Apr;48(4):402-407. https://doi.org/10.1080/02713683.2022.2162925 Epub 2022 Dec 29. PMID: 36576170.
Li Y, Yip M, Ning Y, Chung J, Toh A, Leow C, Liu N, Ting D, Schmetterer L, Saw SM, Jonas JB, Chia A, Ang M. Topical Atropine for Childhood Myopia Control: The Atropine Treatment Long-Term Assessment Study. JAMA Ophthalmol. 2024 Jan 1;142(1):15-23. https://doi.org/10.1001/jamaophthalmol.2023.5467 PMID: 38019503; PMCID: PMC10690578.
Wei S, Li SM, An W, Du J, Liang X, Sun Y, Zhang D, Tian J, Wang N. Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial. JAMA Ophthalmol. 2020 Nov 1;138(11):1178-1184. https://doi.org/10.1001/jamaophthalmol.2020.3820 PMID: 33001210; PMCID: PMC7530823.
Fu A, Stapleton F, Wei L, Wang W, Zhao B, Watt K, Ji N, Lyu Y. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. Br J Ophthalmol. 2020 Nov;104(11):1535-1541. https://doi.org/10.1136/bjophthalmol-2019-315440
Epub 2020 Feb 21. PMID: 32086237.
Chaurasia S, Negi S, Kumar A, Raj S, Kaushik S, Optom RKM, Kishore P, Dogra MR. Efficacy of 0.01% low dose atropine and its correlation with various factors in myopia control in the Indian population. Sci Rep. 2022 May 2;12(1):7113. https://doi.org/10.1038/s41598-022-10079-1 PMID: 35501349; PMCID: PMC9061826.
Xia L, Zhao H, Wang Y. Effect of 0.01% Atropine on diopter and optic axis in adolescents and children with myopia. J Pak Med Assoc. 2023 Mar;73(3):656-658. https://doi.org/10.47391/JPMA.6241 PMID: 36932775.
Moriche-Carretero M, Revilla-Amores R, Diaz-Valle D, Morales-Fernández L, Gomez-de-Liaño R. Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops. J Fr Ophtalmol. 2021 Dec;44(10):1499-1504. https://doi.org/10.1016/j.jfo.2021.07.005 Epub 2021 Nov 10. PMID: 34774348.
Chia A, Ngo C, Choudry N, Yamakawa Y, Tan D. Atropine Ophthalmic Solution to Reduce Myopia Progression in Pediatric Subjects: The Randomized, Double-Blind Multicenter Phase II APPLE Study. Asia Pac J Ophthalmol (Phila). 2023 Jul-Aug 01;12(4):370-376. https://doi.org/10.1097/APO.0000000000000609 Epub 2023 May 10. PMID: 37523428.
Lee SS, Nilagiri VK, Lingham G, Blaszkowska M, Sanfilippo PG, Franchina M, Clark A, Mackey DA. Myopia progression following 0.01% atropine cessation in Australian children: Findings from the Western Australia - Atropine for the Treatment of Myopia (WA-ATOM) study. Clin Exp Ophthalmol. 2024 Jul;52(5):507-515. https://doi.org/10.1111/ceo.14368 Epub 2024 Feb 23. PMID: 38400607.
Agarwal P, Khurana A, Maan V, Sutar S, Chauhan L. Role of 0.01% atropine in high myopic children of Moradabad, India (RAMCOM Study). Indian J Ophthalmol. 2022 Dec;70(12):4400-4404. https://doi.org/10.4103/ijo.IJO_679_22 PMID: 36453353; PMCID: PMC9940541.
Xu S, Li Z, Zhao W, Zheng B, Jiang J, Ye G, Feng Z, Long W, He L, He M, Hu Y, Yang X. Effect of atropine, orthokeratology and combined treatments for myopia control: a 2-year stratified randomised clinical trial. Br J Ophthalmol. 2023 Nov 22;107(12):1812-1817. https://doi.org/10.1136/bjo-2022-321272 PMID: 36229177.
Wang YR, Bian HL, Wang Q. Atropine 0.5% eyedrops for the treatment of children with low myopia: A randomized controlled trial. Medicine (Baltimore). 2017 Jul;96(27):e7371. https://doi.org/10.1097/MD.0000000000007371 PMID: 28682887; PMCID: PMC5502160.
Hansen NC, Hvid-Hansen A, Møller F, Bek T, Larsen DA, Jacobsen N, Kessel L. Safety and efficacy of 0.01% and 0.1% low-dose atropine eye drop regimens for reduction of myopia progression in Danish children: a randomized clinical trial examining one-year effect and safety. BMC Ophthalmol. 2023 Oct 30;23(1):438. https://doi.org/10.1186/s12886-023-03177-9 PMID: 37904082; PMCID: PMC10614417.
Hansen N, Hvid-Hansen A, Møller F, Bek T, Larsen D, Jacobsen N, Kessel L. 3-year results of 0.01% and 0.1% loading dose atropine treatment including washout in Danish children with myopia: a placebo-controlled, randomised clinical trial. Br J Ophthalmol. 2025 Aug 20;109(9):1056-1063. https://doi.org/10.1136/bjo-2024-326918 PMID: 40122578; PMCID: PMC12418564.
Chia A, Burkill S, Ling Y, Quah BL, Tan D, Tay SA, Tay A, Saw SM, Tan DT. Effect of low-dose atropine on young premyopic and low-myopic children: atropine treatment of myopia (ATOM3) - a randomised control trial. Br J Ophthalmol. 2026 Mar 20;110(4):356-362. https://doi.org/10.1136/bjo-2025-328221 PMID: 41862182; PMCID: PMC13018830.
Li FF, Kam KW, Zhang Y, Tang SM, Young AL, Chen LJ, Tham CC, Pang CP, Yam JC. Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study. Ophthalmology. 2020 Dec;127(12):1603-1611. https://doi.org/10.1016/j.ophtha.2020.06.004 Epub 2020 Jun 7. PMID: 32525048.
Pérez-Flores I, Macías-Murelaga B, Barrio-Barrio J; Multicenter Group of Atropine Treatment for Myopia Control (GTAM). A multicenter Spanish study of atropine 0.01% in childhood myopia progression. Sci Rep. 2021 Nov 5;11(1):21748. https://doi.org/10.1038/s41598-021-00923-1 PMID: 34741059; PMCID: PMC8571279.
Loughman J, Kobia-Acquah E, Lingham G, Butler J, Loskutova E, Mackey DA, Lee SSY, Flitcroft DI. Myopia outcome study of atropine in children: Two-year result of daily 0.01% atropine in a European population. Acta Ophthalmol. 2024 May;102(3):e245-e256. https://doi.org/10.1111/aos.15761 Epub 2023 Sep 11. PMID: 37694816.
Saxena R, Gupta V, Thakur H, Dhiman R, Velpandian T, Phuljhele S, Sharma N. Atropine (0.05%) for rapid progressive childhood myopia (ARM study). Indian J Ophthalmol. 2025 Mar 1;73(3):358-361. https://doi.org/10.4103/IJO.IJO_1526_24 Epub 2024 Dec 27. PMID: 39728597; PMCID: PMC11994162.
Zhao Q, Hao Q. Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children. Int Ophthalmol. 2021 Mar;41(3):1011-1017. https://doi.org/10.1007/s10792-020-01658-0 Epub 2020 Nov 17. PMID: 33205372; PMCID: PMC7943497.
Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, Takahashi H, Tanaka S, Kinoshita S; ATOM-J Study Group. Assessment of myopic rebound effect after discontinuation of treatment with 0.01% atropine eye drops in Japanese school-age children. Jpn J Ophthalmol. 2023 Sep;67(5):602-611. https://doi.org/10.1007/s10384-023-01012-8 Epub 2023 Aug 7. PMID: 37548816.
Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L, Swaminathan M, Phuljhele S, Velpandian T, Sharma N. Atropine for the Treatment of Childhood Myopia in India: Multicentric Randomized Trial. Ophthalmology. 2021 Sep;128(9):1367-1369. https://doi.org/10.1016/j.ophtha.2021.01.026 Epub 2021 Feb 2. PMID: 33545170.
Wei S, Li SM, An W, Du J, Liang X, Sun Y, Gan J, Bai W, Tian J, Cai Z, Yin L, Wang N. Myopia progression after cessation of low-dose atropine eyedrops treatment: A two-year randomized, double-masked, placebo-controlled, cross-over trial. Acta Ophthalmol. 2023 Mar;101(2):e177-e184. https://doi.org/10.1111/aos.15235 Epub 2022 Aug 23. PMID: 35999653.
Azuara-Blanco A, Logan NS, McConnell E, Kearney S, Kirk G, Jones S, McDowell C, Murphy L, O'Hanlon G, McFarland M, Painter S, Muthusamy B, Nabili S, Preston J, Flitcroft I, Loughman J, Mackey D, Lee S, Dahlmann-Noor A, Congdon N, Hogg RE, Hammond CJ, Saunders K, Allen PM, Strang N, Clarke M. Low concentration atropine eye drops and progression of myopia in children: multicentre placebo controlled, double masked, randomised trial in the UK (CHAMP-UK). BMJ. 2026 Jun 11;393:e086698. https://doi.org/10.1136/bmj-2025-086698 PMID: 42276557; PMCID: PMC13274572.
Diaz-Llopis M, Pinazo-Durán MD. Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness. Arch Soc Esp Oftalmol (Engl Ed). 2018 Apr;93(4):182-185. English, Spanish. https://doi.org/10.1016/j.oftal.2017.12.015 Epub 2018 Feb 15. PMID: 29398233. [45]
Moriche-Carretero M, Revilla-Amores R, Gutiérrez-Blanco A, Moreno-Morillo FJ, Martinez-Perez C, Sánchez-Tena MÁ, Alvarez-Peregrina C. Five-year results of atropine 0.01% efficacy in the myopia control in a European population. Br J Ophthalmol. 2024 May 21;108(5):715-719. https://doi.org/10.1136/bjo-2022-322808 PMID: 37268328.
Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, Takahashi H, Nakamura Y, Sotozono C, Oshika T, Morimoto T, Nishida K, Nishikawa N, Song YS, Tokutake T, Nishi Y, Shigeno Y, Kurihara T, Negishi K, Tsubota K, Ono M, Nakai T, Tan D, Tanaka S, Kinoshita S; ATOM-J. Study Group. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol. 2021 May;65(3):315-325. https://doi.org/10.1007/s10384-021-00822-y Epub 2021 Feb 14. PMID: 33586090.
Ye L, Shi Y, Yin Y, Li S, He J, Zhu J, Xu X. Effects of Atropine Treatment on Choroidal Thickness in Myopic Children. Invest Ophthalmol Vis Sci. 2020 Dec 1;61(14):15. https://doi.org/10.1167/iovs.61.14.15 PMID: 33320168; PMCID: PMC7745623.
Bai WL, Gan JH, Wei S, Li SM, An WZ, Liang XT, Tian JX, Yin L, Wang N. Effect of low-dose atropine eyedrops on pupil metrics: results after half a year of treatment and cessation. Graefes Arch Clin Exp Ophthalmol. 2023 Apr;261(4):1177-1186. https://doi.org/10.1007/s00417-022-05863-8 Epub 2022 Nov 19. PMID: 36401652; PMCID: PMC9676878.
Lee SS, Lingham G, Blaszkowska M, Sanfilippo PG, Koay A, Franchina M, Chia A, Loughman J, Flitcroft DI, Hammond CJ, Azuara-Blanco A, Crewe JM, Clark A, Mackey DA. Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial. Clin Exp Ophthalmol. 2022 Dec;50(9):1001-1012. https://doi.org/10.1111/ceo.14148
Epub 2022 Sep 9. PMID: 36054556; PMCID: PMC10086806.
Zhang H, Yang P, Li Y, Zhang W, Li S. Effect of Low-Concentration Atropine Eye Drops in Controlling the Progression of Myopia in Children: A One- and Two-Year Follow-Up Study. Ophthalmic Epidemiol. 2024 Jun;31(3):240-248. https://doi.org/10.1080/09286586.2023.2232462 Epub 2023 Aug 1. PMID: 37528608.
Wang Y, Liu F, Zhu X, Liu Y, He JC, Zhou X, Qu X. Effects on radius of curvature and refractive power of the cornea and crystalline lens by atropine 0.01% eye drops. Acta Ophthalmol. 2024 Feb;102(1):e69-e77. https://doi.org/10.1111/aos.15679 Epub 2023 May 4. PMID: 37143398.
Di Meglio M, Giunta P, Rechichi M, Trofa A, Galantuomo G, Galantuomo N, Palmieri S, Pacente L, Salducci M. Treatment of progressive myopia with 0.01% Atropine in children and adolescents: an Italian 4-year follow-up study. Clin Ter. 2024 Sep-Oct;175(5):265-270. https://doi.org/10.7417/CT.2024.5129
PMID: 39400089.
Chan HHL, Choi KY, Ng ALK, Choy BNK, Chan JCH, Chan SSH, Li SZC, Yu WY. Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response. Sci Rep. 2022 Jul 8;12(1):11588. https://doi.org/10.1038/s41598-022-15686-6 PMID: 35804049; PMCID: PMC9270320.
Liang, X., Wei, S., Li, S. M., An, W., Du, J., Sun, Y., Gan, J., Bai, W., Cai, Z., Song, Q., Yin, L., Wang, N. (2023). Effect of Atropine 0.01% Eye Drops on the Difference in Refraction and Axial Length between Right and Left Eyes. Ophthalmic Res, 66(1), 496-505. https://doi.org/10.1159/000528878
Cui C, Li X, Lyu Y, Wei L, Zhao B, Yu S, Rong J, Bai Y, Fu A. Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial. Sci Rep. 2021 Nov 15;11(1):22267. https://doi.org/10.1038/s41598-021-01708-2 PMID: 34782708; PMCID: PMC8592985.
Saxena R, Gupta V, Dhiman R, Phuljhele S, Kumar P, Sharma N, Iribarren R, Rozema J. Effect of low-dose atropine (0.01%) on crystalline lens power among school-aged children with progressive myopia. Ophthalmic Physiol Opt. 2023 Nov;43(6):1406-1411. https://doi.org/10.1111/opo.13192 Epub 2023 Jun 23. PMID: 37350384.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Wiktoria Żelazna, Kalina Światlak, Justyna Trzaskalik, Jakub Sokołowski, Monika Leśniak

This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.

